AMA Research & Media

Prostate Cancer Nuclear Medicine Diagnostics Market May Set New Growth Story : Cancer Genetics, Lantheus Medical Imagining, Theragnostics


NJ New Jersey, USA -- (SBWIRE) -- 09/20/2023 -- Advance Market Analytics published a new research publication on "Prostate Cancer Nuclear Medicine Diagnostics Market Insights, to 2028" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Prostate Cancer Nuclear Medicine Diagnostics market was mainly driven by the increasing R&D spending across the world.

Get Free Exclusive PDF Sample Copy of This Research @

Some of the key players profiled in the study are: Blue Earth Diagnostics (United Kingdom), Lantheus Medical Imagining, Inc. (United States), Theragnostics Ltd (United Kingdom), Curium Pharma (Finland), Jubilant Pharma Limited (United States), NCM-USA LLC (United States), Telix Pharmaceuticals Ltd. (Australia), Cancer Genetics, Inc. (United States), Sun Nuclear Corporation (United States), American Pride (United States).

Scope of the Report of Prostate Cancer Nuclear Medicine Diagnostics
Prostate cancer is cancer that develops in the tissues of the prostate. Prostate cancer is most commonly found in elderly men. Fats promote the synthesis of testosterone and other hormones, and testosterone has been shown to hasten prostate cancer growth. High testosterone levels have been linked to the reactivation of latent prostate cancer cells. Nuclear medicine and radiology both employ radiation. Radioactive materials are known as radioisotopes, or radiopharmaceuticals, are administered into the body in nuclear medicine. X-rays enter the body from the outside in radiology. A wide range of illnesses can be diagnosed using nuclear medicine. A radiopharmaceutical will be given to the patient via inhalation, swallowing, or injection. This substance is radioactive. The patient will often lie down on a table after taking the substance while a camera captures pictures. The camera will focus on the area where the radioactive material is concentrated, allowing the doctor to see what kind of issue exists and where it is located.

The titled segments and sub-section of the market are illuminated below: by Type (Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET)), Application (Hospitals, Clinics, Others), PET product (F-18, C-11, Ga 68 PSMA, Other)

Market Drivers:
The presence of reimbursement policies is expected to further fuel the growth of nuclear medicine diagnostics
Rising Prevalence of Prostate Cancer

Market Trends:
Rising Demand for Early and Precise Diagnosis of the Disease
Increasing research activities for the development of innovative imaging

Adoption of PET as a diagnostic tool is significantly increasing
Increasing demand for PET diagnostic procedures due to higher accuracy

Region Included are: North America, Europe, Asia Pacific, Oceania, South America, Middle East & Africa

Country Level Break-Up: United States, Canada, Mexico, Brazil, Argentina, Colombia, Chile, South Africa, Nigeria, Tunisia, Morocco, Germany, United Kingdom (UK), the Netherlands, Spain, Italy, Belgium, Austria, Turkey, Russia, France, Poland, Israel, United Arab Emirates, Qatar, Saudi Arabia, China, Japan, Taiwan, South Korea, Singapore, India, Australia and New Zealand etc.

Have Any Questions Regarding Global Prostate Cancer Nuclear Medicine Diagnostics Market Report, Ask Our Experts@

Strategic Points Covered in Table of Content of Global Prostate Cancer Nuclear Medicine Diagnostics Market:
Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Prostate Cancer Nuclear Medicine Diagnostics market
Chapter 2: Exclusive Summary – the basic information of the Prostate Cancer Nuclear Medicine Diagnostics Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the Prostate Cancer Nuclear Medicine Diagnostics
Chapter 4: Presenting the Prostate Cancer Nuclear Medicine Diagnostics Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country 2015-2020
Chapter 6: Evaluating the leading manufacturers of the Prostate Cancer Nuclear Medicine Diagnostics market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions (2023-2028)
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

finally, Prostate Cancer Nuclear Medicine Diagnostics Market is a valuable source of guidance for individuals and companies.

Read Detailed Index of full Research Study at @

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Middle East, Africa, Europe or LATAM, Southeast Asia.